Cellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30 p...
February 07 2017 - 4:48PM
Business Wire
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART), today
announced that Dr. André Choulika, Chairman and Chief Executive
Officer of Cellectis, will present at the LEERINK Partners 6th
Annual Global Healthcare Conference on Thursday, February 16, 2017
at 1:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New
York.
To access the live webcast of Cellectis’ presentation, please
visit http://www.cellectis.com/en/events. A replay of the webcast
will be available on Cellectis’ website for 90 days.
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
17 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases as well as its pioneering
electroporation PulseAgile technology - to create a new generation
of immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets. Cellectis is
listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit
our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170207006521/en/
CellectisMedia:Jennifer Moore, 917-580-1088,VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2023 to Sep 2024